DNA Vaccine

Source: au.rd.yahoo.com --- 35 days ago
WASHINGTON (Reuters) - A DNA-based Vaccine against avian influenza can safely stimulate the immune system to levels expected to protect against flu, San Diego-based Vical Inc reported on Thursday. ...

Source: au.rd.yahoo.com --- 35 days ago
Corrects test details, paragraph 2. ...

Source: www.moreover.com --- 50 days ago
PHILADELPHIA, July 1 (AScribe Newswire) -- Researchers at the University of Pennsylvania School of Medicine have identified a potential new way to vaccinate against avian flu. ...

Source: www.moreover.com --- 31 days ago
MAY 28 -- Ichor Medical Systems announced it has received FDA approval to conduct a Phase I of a to be administered to patients utilizing a novel delivery technology. ...

Source: www.ncbi.nlm.nih.gov --- 26 days ago
Related Articles A novel DNA Vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther. 2008 Jul 24; Authors: Tohyama S, Onodera S, Tohyama H, Yasuda K, Nishihira J, Mizue Y, Hamasaka A, Abe R, Koyama Y Sepsis is a common and frequently fatal condition and there is an urgent need for new therapies that will further reduce sepsis-induced mortality. Macrophage migration inhibitory (MIF) factor is important in the regulation of innate and adaptive immunity and is believed to play a key regulatory role in sepsis and autoimmune disease. As MIF deficiency or immunoneutralization protects mice or rats from fatal endotoxic shock or other inflammatory diseases, we examined whether DNA vaccination against this molecule would also be protective. DNA vaccines can stimulate both humoral and cellular immunity simultaneously and have been shown to be effective against a variety of pathogens or cytokine-driven pathologies. Mice were immunized with a MIF/tetanus toxin (TTX) DNA Vaccine and sepsis was then induced by lipopolysaccharide or cecal ligation and puncture. The MIF/TTX DNA-vaccinated mice were protected from the lethal effect of sepsis compared with control-vaccinated mice in both models. Compared with the control-vaccinated mice, the MIF/TTX DNA-vaccinated mice also showed significantly lower serum tumor necrosis factor (TNF)-alpha protein levels and reduced mRNA expression of TNF-alpha, in ...

Source: www.moreover.com --- 54 minutes ago
/PRNewswire-FirstCall/ -- Vical Incorporated today announced that results from nonhuman primate studies of a Vaxfectin(R)-formulated DNA Vaccine for measles, published in the August issue of Clinical and Vaccine Immunology(1), offer a promising ...

Source: www.moreover.com --- 54 minutes ago
, 2:30 AM EST In the article, authors from the Johns Hopkins Bloomberg School of Public Health, the Johns Hopkins School of Medicine The measles studies were conducted in collaboration with Diane E. Griffin Vaxfectin(R)-formulated Measles DNA Vaccine ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles A Nasal IL-12 DNA Vaccine Co-Expressing Yersinia pestis F1-V Fusion Protein Confers Protection against Pneumonic Plague. Infect Immun. 2008 Aug 11; Authors: Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K, Becker T, Maddaloni M, Pascual DW Previous studies have shown that mucosal application of IL-12 can stimulate elevated secretory IgA (S-IgA) responses. Since possible exposure to plague is via Yersinia pestis- laden aerosols that results in pneumonic plague, arming both the mucosal and systemic immune systems may offer an added benefit for protective immunity. Two bicistronic plasmids were constructed that encoded the protective plague epitopes, capsular (F1) antigen and virulence antigen (V-Ag) as a F1-V fusion protein, but differed in the amounts of IL-12 produced. When applied nasally, serum IgG and mucosal IgA anti-F1- and anti-V-Ag titers were detectable beginning at wk 6 after three weekly doses, and recombinant F1-Ag boosts were required to elevate the F1-Ag-specific antibody (Ab) titers. Following pneumonic challenge, the best efficacy was obtained in mice primed with IL-12(Low)/F1-V Vaccine with 80% survival when compared to mice immunized with IL-12(Low)/F1, IL-12(Low)/V, or IL-12(Low) vector DNA vaccines. Improved expression of IL-12 resulted in lost efficacy when using the IL-12(High)/F1-V DNA Vaccine. Despite differences in the amount of IL-12 produced by the two F1-V DNA vaccines, Ab responses ...

Source: www.ncbi.nlm.nih.gov --- 8 days ago
Related Articles Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus Macaques by a novel HCV genotype 1a/1b consensus DNA Vaccine. Vaccine. 2008 Aug 6; Authors: Lang KA, Yan J, Draghia-Akli R, Kahn A, Weiner DB Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no Vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA Vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus Macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines. PMID: 18692108 [PubMed - as supplied by publisher] ...

Source: www.moreover.com --- 35 days ago
Washington - A DNA-based Vaccine against avian influenza can safely stimulate the immune system to levels expected to protect against flu, San Diego-based Vical Inc reported on Thursday. ...

Source: www.ncbi.nlm.nih.gov --- 13 days ago
Related Articles Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA Vaccine. Immunol Lett. 2008 Jun 15;118(1):65-71 Authors: Dutta NK, Mazumdar K, Lee BH, Baek MW, Kim DJ, Na YR, Park SH, Lee HK, Kariwa H, Mai le Q, Park JH It is believed today that nucleocapsid protein (N) of severe acute respiratory syndrome (SARS)-CoV is one of the most promising antigen candidates for Vaccine design. In this study, three fragments [N1 (residues: 1-422); N2 (residues: 1-109); N3 (residues: 110-422)] of N protein of SARS-CoV were expressed in Escherichia coli and analyzed by pooled sera of convalescence phase of SARS patients. Three gene fragments [N1 (1-1269 nt), N2 (1-327 nt) and N3 (328-1269 nt)-expressing the same proteins of N1, N2 and N3, respectively] of SARS-N were cloned into pVAX-1 and used to immunize BALB/c mice by electroporation. Humoral (by enzyme-linked immunosorbent assay, ELISA) and cellular (by cell proliferation and CD4(+):CD8(+) assay) immunity was detected by using recombinant N1 and N3 specific antigen. Results showed that N1 and N3 fragments of N protein expressed by E. coli were able to react with sera of SARS patients but N2 could not. Specific humoral and cellular immunity in mice could be induced significantly by inoculating SARS-CoV N1 and N3 DNA Vaccine. In addition, the immune response levels in N3 were significantly higher for antibody responses (IgG and IgG1 but not IgG2a ...

Source: www.ncbi.nlm.nih.gov --- 19 days ago
Related Articles Multiple Alternating Immunizations with DNA Vaccine and Replicationin competent Adenovirus Expressing gB of Pseudorabies Virus Protect Animals Against Lethal Virus Challenge. J Microbiol Biotechnol. 2008 Jul;18(7):1326-34 Authors: Kim SJ, Kim HK, Han YW, Aleyas AG, George JA, Yoon HA, Yoo DJ, Kim K, Eo SK The prime-boost vaccination with DNA Vaccine and recombinant viral vector has emerged as an effective prophylactic strategy to control infectious diseases. Here, we compared the protective immunities induced by multiple alternating immunizations with DNA Vaccine (pCIgB) and replication-incompetent adenovirus (Ad-gB) expressing glycoprotein gB of pseudorabies virus (PrV). The platform of pCIgB-prime and Ad-gB-boost induced the most effective immune responses and provided protection against virulent PrV infection. However, priming with pCIgB prior to vaccinating animals by the DNA vaccineprime and Ad-boost protocol provided neither effective immune responses nor protection against PrV. Similarly, boosting with Ad-gB following immunization with DNA Vaccine-prime and Ad-boost showed no significant responses. Moreover, whereas the administration of Ad-gB for primary immunization induced Th2-type-biased immunity, priming with pCIgB induced Th1-type-biased immunity, as judged by the production of PrV-specific IgG isotypes and cytokine IFN-gamma. These results indicate that the order and injection frequency of Vaccine vehicle ...

Source: www.moreover.com --- 35 days ago
It said tests on 100 volunteers showed 67 had immune responses that could protect against infection with the H5N1 avian flu virus, with no serious adverse reactions after two injections. ...

Source: www.moreover.com --- 35 days ago
WASHINGTON (Reuters) - A DNA-based Vaccine against avian influenza can safely stimulate the immune system to levels expected to protect against flu, San Diego-based Vical Inc reported on Thursday. ...

Source: www.emediawire.com --- 7 days ago
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to ensuring the development of safe and effective preventive HIV vaccines. Inovio's electroporation delivery technology is intended to enhance the potency of DNA vaccines against cancers and infectious diseases by increasing the cellular uptake of an agent by 1,000 times or more. This technology also has the potential to induce significant antibody and T-cell immune responses, both of which scientists believe will be critical to developing a preventive HIV Vaccine. (PRWEB Aug 14, 2008) Read the full story at http://www.emediawire.com/releases/Vaccine/inovio/prweb1211794.htm ...

Source: ca.prweb.com --- 13 days ago
Inovio Biomedical Corporation (AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2008. (PRWeb Aug 7, 2008) Read the full story at http://ca.prweb.com/releases/million/june_30/prweb1189394.htm ...

Source: www.businesswire.com --- 37 days ago
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling ...

Source: www.medicalnewstoday.com --- 5 days ago
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to ensuring the development of safe and effective preventive HIV vaccines. ...

Source: www.medicalnewstoday.com --- 48 days ago
VGX Pharmaceuticals, Inc. (VGX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its DNA Vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available ...

Source: forums.canadiancontent.net --- 50 days ago
URGENT WARNING: H5N1 DNA in Flu Vaccine http://uk.youtube.com/watch?v=zcniJxck0gI avian flu what are they up too millions of people in britain... ...